How we help you power through the challenges of in vivo CAR-T development

Balancing in vivo potency and safety
Achieve targeted, durable CAR expression while limiting off-target toxicity and immune reactions

Complex formulation and conjugation
Combine genetic payloads with delivery systems deliver precise control

Expanded analytical requirements
Advanced bioanalytical methods are used to characterize both vector and formulation attributes

Cross-modality GMP scale-up
End-to-end solutions manage viral vector or RNA-LNP production, formulation, and fill/finish

New regulatory questions
CMC submissions in this area face especially strict standards, requiring flawless quality, safety, and clinical alignment
How we know what you need

Commercial track record of mRNA vaccines and viral vectors for
ex vivo CAR-T

Supporting multiple in vivo CAR-T programs, including clinical manufacturing

Fully integrated development and manufacturing

Decades of GMP experience in cell
and gene therapies
For Viral Vectors, you need Lonza
Technical expert guidance for emerging in vivo CAR-T programs
Proven platforms for high-yield viral vector scale-up
Advanced analytics for complex viral vector characterization
Experienced and reliable commercial-scale manufacturing
End-to-end regulatory and CMC support for a rapidly evolving field
Proven end-to-end supports for process development, tech transfers, GMP manufacturing, and pre-license inspection readiness
FDA-approved Houston site for commercial viral vector production
For mRNA, you need Lonza
Process scale-up for complex in vivo modalities
Multiple payload encapsulation
Deep characterization
Pioneering in vivo CAR-T/gene editing
Check out our recent webinar looking at the critical factors shaping the development of complex RNA-based CAR-T therapies.
We cover quality requirements, delivery challenges, and innovative process design from linker selection and LNP encapsulation to analytical hurdles.
Learn about strategies for development through IND, overcoming scale-up challenges, and ensuring reproducibility for next-generation in vivo CAR-T treatments.
Let’s supercharge your in vivo CAR-T program
Tell us about your program and how we can help you bring in vivo CAR-T therapies to your patients.